Investing.com -- Shares in Hims Hers Health Inc (NYSE:HIMS) soared over 40% on Tuesday after the telehealth group announced a "long-term collaboration" with Novo Nordisk A/S (NYSE:NVO) to offer the Danish firm’s blockbuster Wegovy obesity drug on its platform.

In a statement, Hims & Hers said Americans will have access to a bundled offering that includes all dose strengths of Wegovy.

From this week, the treatment will be available at a "single, unified price" starting at $599 per month on the Hims & Hers platform.

Both companies said they are also developing a roadmap that combines Novo’s "innovative treatments" and Hims & Hers’ "ability to scale access to quality care."

Hims & Hers added that its platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.

Earlier this month, Hims & Hers said it was planning to sell Eli Lilly (NYSE:LLY)’s weight-loss drug, as part of a bid to widen its offerings to offset a possible impact from restrictions on selling copies of Wegovy.

Shares in Hims & Hers were hit in February after U.S. drug regulators removed Wegovy and the diabetes drug Ozempic, both of which are known chemically as semaglutide, from its shortage list.

Their presence on this list had allowed Hims & Hers to sell cheaper versions of Novo’s semaglutide.

Related articles

Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk

TD Cowen downgrades Hims & Hers Health to Hold on GLP-1 headwinds,

Amazon falls after White House calls plan to add tariff pricing ’hostile act’